Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

Inclusion Criteria: 1. Newly diagnosed intermediate and high-risk AML according to the WHO (2022) classification of acute myeloid leukemia (non-APL). 2. Age 18-65. 3. ECOG score: 0-2. 4. No history of previous chemotherapy or target therapy. 5. Serum total bilirubin \<= 2 times the upper limit of normal (ULN), alanine aminotransferase (ALT) \<= 1.5 times ULN, aspartate aminotransferase (AST) \<=1.5 times ULN; 6. Creatinine clearance rate \>=30 mL/min; 7. Serum lipase \<= 1.5 times ULN, amylase \<= 1.5 times ULN; 8. Capable to understand and willing to participate in this study, signed the informed consent form. Exclusion Criteria: 1. AML transformed with chronic myelogenous leukemia. 2. Acute promyelocytic leukemia (type M3). 3. Patients with a second malignancy requiring treatment. 4. Patients with uncontrolled active infection. 5. Patients with left ventricular ejection fraction \< 0.5 by echocardiography or grade III/IV cardiovascular dysfunction according to the New York Heart Association Classification. 6. Patients with hepatic and renal inadequacy: total serum bilirubin \>=2.0 mg/dl, AST \>=3 times ULN, serum creatinine clearance (Ccr) \<50 ml / min. 7. Patients with arterial oxygen saturation (SpO 2) was \<95%. 8. Patients with HIV infection. 9. Patients with active hepatitis B or hepatitis C infection. 10. Patients with other commodities that the investigators considered not suitable for the enrollment.